Connection

Co-Authors

This is a "connection" page, showing publications co-authored by MICHAEL TETZLAFF and CARLOS ANTONIO TORRES CABALA.
  1. Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. Hum Pathol. 2015 Aug; 46(8):1101-10.
    View in: PubMed
    Score: 0.513
  2. Use of clinical next-generation sequencing to identify melanomas harboring SMARCB1 mutations. J Cutan Pathol. 2015 May; 42(5):308-17.
    View in: PubMed
    Score: 0.509
  3. Histological features associated with vemurafenib-induced skin toxicities: examination of 141 cutaneous lesions biopsied during therapy. Am J Dermatopathol. 2014 Jul; 36(7):557-61.
    View in: PubMed
    Score: 0.484
  4. Melanoma arising in association with blue nevus: a clinical and pathologic study of 24 cases and comprehensive review of the literature. Mod Pathol. 2014 Nov; 27(11):1468-78.
    View in: PubMed
    Score: 0.477
  5. Pigmented extramammary Paget disease of the thigh mimicking a melanocytic tumor: report of a case and review of the literature. J Cutan Pathol. 2014 Jun; 41(6):529-35.
    View in: PubMed
    Score: 0.475
  6. Ambiguous melanocytic tumors in a tertiary referral center: the contribution of fluorescence in situ hybridization (FISH) to conventional histopathologic and immunophenotypic analyses. Am J Surg Pathol. 2013 Dec; 37(12):1783-96.
    View in: PubMed
    Score: 0.464
  7. Immunodetection of phosphohistone H3 as a surrogate of mitotic figure count and clinical outcome in cutaneous melanoma. Mod Pathol. 2013 Sep; 26(9):1153-60.
    View in: PubMed
    Score: 0.444
  8. The utility of ATF3 in distinguishing cutaneous squamous cell carcinoma among other cutaneous epithelial neoplasms. J Cutan Pathol. 2012 Aug; 39(8):762-8.
    View in: PubMed
    Score: 0.421
  9. Prognostic Implication of Lymphovascular Invasion Detected by Double Immunostaining for D2-40 and MITF1 in Primary Cutaneous Melanoma. Am J Dermatopathol. 2016 Jul; 38(7):484-91.
    View in: PubMed
    Score: 0.139
  10. HTLV-1-associated infective dermatitis demonstrates low frequency of FOXP3-positive T-regulatory lymphocytes. J Dermatol Sci. 2015 Mar; 77(3):150-5.
    View in: PubMed
    Score: 0.126
  11. Shared clonality in distinctive lesions of lymphomatoid papulosis and mycosis fungoides occurring in the same patients suggests a common origin. Hum Pathol. 2015 Apr; 46(4):558-69.
    View in: PubMed
    Score: 0.125
  12. p40 is more specific than p63 for the distinction of atypical fibroxanthoma from other cutaneous spindle cell malignancies. Am J Surg Pathol. 2014 Aug; 38(8):1102-10.
    View in: PubMed
    Score: 0.122
  13. The differential diagnosis of CD8-positive ("type D") lymphomatoid papulosis. J Cutan Pathol. 2014 Feb; 41(2):88-100.
    View in: PubMed
    Score: 0.115
  14. Immune Checkpoint Inhibitor Therapy as an Eye-Preserving Treatment for Locally Advanced Conjunctival Melanoma. Ophthalmic Plast Reconstr Surg. 2021 Jan-Feb 01; 37(1):e9-e13.
    View in: PubMed
    Score: 0.047
  15. Primary cutaneous CD30(+) lymphoproliferative disorders. J Dtsch Dermatol Ges. 2016 Aug; 14(8):767-82.
    View in: PubMed
    Score: 0.035
  16. Panniculitis With Necrotizing Granulomata in a Patient on BRAF Inhibitor (Dabrafenib) Therapy for Metastatic Melanoma. Am J Dermatopathol. 2015 Aug; 37(8):e96-9.
    View in: PubMed
    Score: 0.033
  17. Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma. J Cutan Pathol. 2014 Mar; 41(3):326-8.
    View in: PubMed
    Score: 0.029
  18. Impact of the 2009 (7th edition) AJCC melanoma staging system in the classification of thin cutaneous melanomas. Biomed Res Int. 2013; 2013:898719.
    View in: PubMed
    Score: 0.029
  19. Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. Int J Dermatol. 2014 Mar; 53(3):376-84.
    View in: PubMed
    Score: 0.028
  20. Changes in tumor morphology and cyclin-dependent kinase inhibitor expression in metastatic melanoma treated with selective second-generation BRAF inhibitor. Am J Dermatopathol. 2013 Feb; 35(1):125-8.
    View in: PubMed
    Score: 0.027
  21. Molecular platforms utilized to detect BRAF V600E mutation in melanoma. Semin Cutan Med Surg. 2012 Dec; 31(4):267-73.
    View in: PubMed
    Score: 0.027
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.